Buffalo Rheumatology — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2024	Research	$76,253	9
2023	Research	$30,429	14
2022	Research	$16,628	4
2021	Research	$28,892	4
2020	Research	$54,788	5
2019	Research	$136,752	5

Breakdown

Who paid Research payments · program years 2019–2024

Eli Lilly and Company $183,110 7 payments
Novartis Pharmaceuticals Corporation $106,164 4 payments
Janssen Research & Development, LLC $48,537 24 payments
Regeneron Pharmaceuticals, Inc. $4,781 5 payments
Sandoz Inc. $1,150 1 payment

Studies the money was for Research payments · program years 2019–2024

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study of Baricitinib in Patients With Systemic Lupus Erythematosus $109,187 4 payments
A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 We $99,914 2 payments
Taltz Psa Observational Study $65,369 2 payments
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent $48,537 24 payments
Taltz Psa Observational Study $8,554 1 payment
A Phase 3 Randomized, Double-Blind, Multi-Dose, Placebo and Naproxen-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Pain Due to Osteoarthritis of the Knee Or Hip $4,781 5 payments
A Randomized, Double-Blind, Parallel-Group, Multicenter Study of Secukinumab to Compare 300 MG and 150 MG at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During An Initial 16 Week Open-Label Treatment With Secukinumab 150 Mg(Asleap) $4,500 1 payment
A Randomized Double Blind Placebo Controlled Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of Cosentyx Secukinumab 150 MG in Adult Subjects With Active Psoriatic Arthritis After 16 Weeks of Treatment Compared to Placebo $1,750 1 payment
A Randomized Double-Blind Parallel-Group Phase III Study to Demonstrate Equivalent Efficacy and to Compare Safety & Immunogenicity of Gp2015 and Enbrel? (EU Authorized) in Patients With Moderate to Severe Active Rheumatoid Arthritis $1,150 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.